390 related articles for article (PubMed ID: 27394428)
21. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety.
Gopaul A; Kanagalingam T; Thain J; Khan T; Cowan A; Sultan N; Clemens KK
Arch Osteoporos; 2021 Jul; 16(1):116. PubMed ID: 34319515
[TBL] [Abstract][Full Text] [Related]
22. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
23. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
24. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
[TBL] [Abstract][Full Text] [Related]
26. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
27. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
[TBL] [Abstract][Full Text] [Related]
28. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
29. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
Coskun Benlidayi I
Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
[TBL] [Abstract][Full Text] [Related]
30. The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients.
Horikawa A; Hongo M; Kasukawa Y; Shimada Y; Kodama H; Sano A; Miyakoshi N
J Bone Miner Metab; 2022 Jul; 40(4):670-676. PubMed ID: 35641798
[TBL] [Abstract][Full Text] [Related]
31. [Is denosmab really effective and safe in the care of CKD-MBD?].
Hamano T; Nakano C
Clin Calcium; 2016 Sep; 26(9):1309-17. PubMed ID: 27561346
[TBL] [Abstract][Full Text] [Related]
32. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
[TBL] [Abstract][Full Text] [Related]
33. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis.
Shrosbree JE; Elder GJ; Eisman JA; Center JR
Intern Med J; 2018 Jun; 48(6):681-687. PubMed ID: 29363863
[TBL] [Abstract][Full Text] [Related]
34. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
35. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
36. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
Kang MY; Besley J; Sun T; Paul S
N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
[TBL] [Abstract][Full Text] [Related]
38. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Tsvetov G; Amitai O; Shochat T; Shimon I; Akirov A; Diker-Cohen T
Osteoporos Int; 2020 Apr; 31(4):655-665. PubMed ID: 31838550
[TBL] [Abstract][Full Text] [Related]
39. [Changes of serum calcium and bone turnover markers in maintenance hemodialysis patients treated with denosumab].
Wang Y; Zhu L; Yang B; Gan LY; Zuo L
Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):594-597. PubMed ID: 36822871
[TBL] [Abstract][Full Text] [Related]
40. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
Hiramatsu R; Ubara Y; Sawa N; Sakai A
Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
